Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Hatzl, S; Kriegl, L; Posch, F; Schilcher, G; Eller, P; Reisinger, A; Grinschgl, Y; Muhr, T; Meinitzer, A; Hoenigl, M; Krause, R.
Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation.
J Antimicrob Chemother. 2023; 78(12):2902-2908
Doi: 10.1093/jac/dkad328
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Hatzl Stefan
- Krause Robert
- Co-authors Med Uni Graz
- Eller Philipp
- Grinschgl Yvonne
- Hönigl Martin
- Kriegl Lisa
- Meinitzer Andreas
- Posch Florian
- Reisinger Alexander Christian
- Schilcher Gernot
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: In critically ill patients with extracorporeal membrane oxygenation (ECMO) attainment of target concentration of isavuconazole is delayed using the routine loading dose. OBJECTIVES: We investigated the influence of increasing the first loading dose of isavuconazole on plasma concentrations in critically ill patients treated with ECMO. METHODS: Fifteen patients were included in this study, and isavuconazole concentrations were measured at several timepoints starting 2 h after the first isavuconazole dose up to 168 h. By interim analysis of isavuconazole concentrations and meticulous screening for adverse events, the first loading dose was stepwise increased from 200 to 300 mg, and finally to 400 mg. RESULTS: Seven of 15 patients (47%) received standard isavuconazole loading dosage with 200 mg as the first dose, 3/15 (20%) received 300 mg, and 5/15 (33%) received 400 mg isavuconazole as the first dose, followed by subsequent standard dosing in all patients. In patients receiving 400 mg as the first dose all isavuconazole concentrations were significantly higher at timepoints up to the first 24 h, resulting in higher proportions of isavuconazole concentrations ≥1 mg/L compared with patients with other loading dosages. In timepoints ≥24 h after isavuconazole initiation all patient groups reached comparable plasma concentrations, regardless of the first loading dose regimen. We did not observe concentrations above ≥5 mg/L or any adverse events related to isavuconazole administration. CONCLUSIONS: In critically ill patients with ECMO the 400 mg loading dose of isavuconazole resulted in immediate median isavuconazole plasma concentrations ≥1 mg/L and remained constant above this threshold after the first loading dose.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Extracorporeal Membrane Oxygenation - methods
- Critical Illness - therapy
- Nitriles - administration & dosage
- Pyridines - administration & dosage